title: [Osteoporosis].
abstract: Type 2 diadetes is associated with an increased risk of fractures. Calcium supplements are still in the middle of a cardiovascular controversy. Swiss recommandations are available for vitamin D supplementation. Zoledronate exerts a long-term remaining effect on bone resorption. After 5 years treatment with denosumab, fracture incidence remains low. Atypical femoral fractures associated with bisphosphonates treatment have been evaluated in the university hospital of Geneva.
authors: Service des maladies osseuses, Département des spécialités de médecine, HUG et Faculté de medecine, 1211 Geneve 14. brigitte.uebelhart@hcuge.ch
authors: B
authors: B
authors: Uebelhart
authors: R
authors: R
authors: Rizzoli
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D002136:Calcium, Dietary / Q000008:administration & dosage; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D009751:Nutritional Requirements; D010024:Osteoporosis / Q000209:etiology* / Q000517:prevention & control*; D058866:Osteoporotic Fractures / Q000517:prevention & control*; D014807:Vitamin D / Q000627:therapeutic use
chemical_list: D050071:Bone Density Conservation Agents; D002136:Calcium, Dietary; D004164:Diphosphonates; D014807:Vitamin D